News
VRAY
4.810
-0.21%
-0.010
Susan Schnabel Just Bought 33% More Shares In ViewRay, Inc. (NASDAQ:VRAY)
Investors who take an interest in ViewRay, Inc. ( NASDAQ:VRAY ) should definitely note that insider Susan Schnabel...
Simply Wall St. · 1d ago
Insider Buy: Viewray
Insider Buy: Viewray
MT Newswires · 2d ago
What 4 Analyst Ratings Have To Say About ViewRay
Benzinga · 11/18 14:08
Morgan Stanley Maintains Equal-Weight on ViewRay, Raises Price Target to $5.5
Benzinga · 11/18 13:02
--Morgan Stanley Adjusts Price Target on ViewRay to $5.50 From $5, Maintains Equal-Weight Rating
--Morgan Stanley Adjusts Price Target on ViewRay to $5.50 From $5, Maintains Equal-Weight Rating
MT Newswires · 11/18 10:18
--B. Riley Resumes ViewRay With Buy Rating, $8 Price Target
--B. Riley Resumes ViewRay With Buy Rating, $8 Price Target
MT Newswires · 11/17 07:40
ViewRay announces $125M debt facility
Seekingalpha · 11/15 13:53
BRIEF-ViewRay Expands Access To Non-Dilutive Capital With New Debt Facility
Reuters · 11/14 22:34
ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference
ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside...
PR Newswire · 11/14 11:30
Morgan Stanley Maintains Equal-Weight on ViewRay, Raises Price Target to $5
Benzinga · 11/02 12:38
Piper Sandler Maintains Overweight on ViewRay, Raises Price Target to $6.5
Benzinga · 11/02 10:35
ViewRay's Q3 Loss Narrows, Revenue Climbs; Lifts Bottom End of 2022 Revenue Outlook Range
ViewRay's Q3 Loss Narrows, Revenue Climbs; Lifts Bottom End of 2022 Revenue Outlook Range
MT Newswires · 11/02 04:34
ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/01 22:45
ViewRay GAAP EPS of -$0.14 in-line, revenue of $26.5M beats by $1.69M
Seekingalpha · 11/01 21:28
ViewRay GAAP EPS of -$0.14, revenue of $26.49M
Seekingalpha · 11/01 21:21
ViewRay Q3 EPS $(0.14), Inline, Sales $26.49M Beat $25.02M Estimate
Benzinga · 11/01 21:20
BRIEF-Viewray Announces Third Quarter 2022 Results
Reuters · 11/01 21:20
-- Earnings Flash (VRAY) VIEWRAY Reports Q3 Revenue $26.5M
-- Earnings Flash (VRAY) VIEWRAY Reports Q3 Revenue $26.5M
MT Newswires · 11/01 17:23
Earnings Scheduled For November 1, 2022
Benzinga · 11/01 08:36
Notable earnings after Tuesday's close
Seekingalpha · 10/31 21:35
More
Webull provides a variety of real-time VRAY stock news. You can receive the latest news about Viewray through multiple platforms. This information may help you make smarter investment decisions.
About VRAY
ViewRay, Inc. is engaged in designing, manufacturing, and marketing the MRIdian MRI-Guided Radiation Therapy System. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumor from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The Company has installed approximately 48 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.